RE:Posted on LinkedIn Reading that it seems Thera will update the clinical situation with a press release before his presentation.
“The presentation will cover the preclinical and clinical development of our lead PDC candidate, TH1902 (sudocetaxel zendusortide). It will touch on the obstacles we overcame transitioning TH1902 from the preclinical to the clinical setting, the challenges we continue to face, and our key learnings." Also, he is talking a lot about the platform, alternative payloads, instead of only TH1902. To me, it tends to indicate that they have the proof of concept, but they still don't understand why it's not working more effectively. The concept works, but there are problems. Wrong payload? Wrong linker? Poor patient selection? He talks about SN38, si RNA, but still no reference to radionuclides. Hard to understand why they don't even talk about it as a possibility.
To me, it looks like the NASH situation. He talks about the investments needed to develop new approaches like PDCs. So it looks like they are looking for partnerships in oncology. I think they realized they have a valuable asset with probably some data to back a proff of concept, not for TH1902, but for the SORT1 platform, ans they don't have the financial ressources to push it farther by themselves. So as for NASH, they are looking for a partner. He does not say it clearly, but that's my feeling after reading between the lines.